本文へスキップ

腫瘍免疫を臨床の視点より研究する塩野義製薬との共同研究講座です。

TEL. 06-6210-8413

〒565-0871 大阪府吹田市山田丘2-2(0803B)

業績

2020年
2019年
2018年
2017年
2016年
2015年
2014年

2013年


  • 2020年
    1. Clinical importance of the expression of CD4+CD8+ T cells in Renal Cell Carcinoma.
    Nishida K, Kawashima A, Kanazawa T, Kidani Y, Yoshida T, Hirata M, Yamamoto K, Yamamoto Y, Sawada M, Kato R, Kato T, Hatano K, Ujike T, Fujita K, Uemura M, Morimoto-Okazawa A, Iwahori K, Yamasaki M, Ohkura N, Sakaguchi S, Nonomura N, Doki Y, Wada H.
    Int Immunol. 2020 Jan 17. pii: dxaa004. doi: 10.1093/intimm/dxaa004.

    2. Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer
    Yamamoto K, Makino T, Sato E, Noma T, Urakawa S, Takeoka T, Yamashita K, Saito T, Tanaka K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Mori M, Doki Y, Wada H.
    Cancer Sci. 2020 Jan 24. doi: 10.1111/cas.14328.

    3. Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating NK cells in intrahepatic cholangiocarcinoma.
    Fukuda Y, Asaoka T, Eguchi H, Yokota Y, Kubo M1, Kinoshita M, Urakawa S, Iwagami Y, Tomimaru Y, Akita H, Noda T, Gotoh K, Kobayashi S, Hirata M, Wada H, Mori M, Doki Y.
    Cancer Sci. 2020 Feb;111(2):323-333. doi: 10.1111/cas.14267. Epub 2020 Jan 23.

    4. Docetaxel Upregulates HMGB1 Levels in Non-small Cell Lung Cancer.
    Haruna M, Hirata M, Iwahori K, Kanazawa T, Yamamoto Y, Goto K, Kawashima A, Morimoto-Okazawa A, Funaki S, Shintani Y, Kumanogoh A, Wada H.
    Biol Pharm Bull. 2020;43(3):399-403. doi: 10.1248/bpb.b19-00702.

    5. Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma
    Atsunari Kawashima, Takayuki Kanazawa, Yujiro Kidani, Tetsuya Yoshida, Michinari Hirata, Kentaro Nishida, Satoshi Nojima, Yoshiyuki Yamamoto, Taigo Kato, Koji Hatano, Takeshi Ujike, Akira Nagahara, Kazutoshi Fujita, Akiko Morimoto-Okazawa, Kota Iwahori, Motohide Uemura, Ryoichi Imamura, Naganari Ohkura, Eiichi Morii, Shimon Sakaguchi, Hisashi Wada, and Norio Nonomura
    Sci Rep. 2020; 10: 6220. doi: 10.1038/s41598-020-63060-1

    6. Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors
    Yoko Yamamoto, Kota Iwahori, Soichiro Funaki, Mitsunobu Matsumoto, Michinari Hirata, Tetsuya Yoshida, Ryu Kanzaki, Takashi Kanou, Naoko Ose, Masato Minami, Eiichi Sato, Atsushi Kumanogoh, Yasushi Shintani, Meinoshin Okumura, Hisashi Wada
    Sci Rep. 2020; 10: 4064. Published online 2020 Mar 4. doi: 10.1038/s41598-020-61053-8

    7. PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer
    Masaaki Sawada, Kumiko Goto, Akiko Morimoto-Okazawa, Miya Haruna, Kei Yamamoto, Yoko Yamamoto, Satoshi Nakagawa, Kosuke Hiramatsu, Shinya Matsuzaki, Eiji Kobayashi, Atsunari Kawashima, Michinari Hirata, Kota Iwahori, Toshihiro Kimura, Yutaka Ueda, Tadashi Kimura, Hisashi Wada
    Int Immunol. 2020 Feb 3. pii: dxaa010. doi: 10.1093/intimm/dxaa010.  PMID: 32009163

    8. 癌免疫療法の歴史 和田 尚
    臨牀消化器内科 5月号 特集免疫チェックポイント阻害薬の現状・今後の展望
    Vol.35、No.5 447-453 2020
  • 2019年
    1. Peri-operative monocyte count is a marker of poor prognosis in gastric cancer: increased monocytes are a characteristic of myeloid-derived suppressor cells.
    Shinya Urakawa, Makoto Yamasaki, Kumiko Goto, Miya Haruna, Michinari Hirata, Akiko Morimoto-Okazawa, Atsunari Kawashima, Kota Iwahori, Tomoki Makino, Yukinori Kurokawa, Tomomi Yamada, Masaki Mori, Yuichiro Doki, Hisashi Wada.    
    Cancer Immunology, Immunotherapy August 2019, Volume 68, Issue 8, pp 1341–1350

    2. Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment.
    Iwahori K, Shintani Y, Funaki S, Yamamoto Y, Matsumoto M, Yoshida T, Morimoto-Okazawa A, Kawashima A, Sato E, Gottschalk S, Okumura M, Kumanogoh A, Wada H.
    Sci Rep. 2019 Feb 22;9(1):2636. doi:10.1038/s41598-019-39345-5. PMID: 30796310

    3. Phenotypic Analysis of Tumor Tissue-Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma.
    Kawashima A, Kanazawa T, Jingushi K, Kato T, Ujike T, Nagahara A, Fujita K, Morimoto-Okazawa A, Iwahori K, Uemura M, Imamura R, Wada H, Nonomura  
    N. Clin Genitourin Cancer. 2019 Apr;17(2):114-124. doi: 10.1016/j.clgc.2018.11.004. PMID: 30555025

    4. コラム先人の足跡 ジェームズ・アリソン
     和田 尚、中山睿一 がん免疫療法 Vol.3 No.2 p.50-51, 2019 11月

    5. 癌免疫療法の更なる発展を願って 和田 尚
     生産と技術 vol.71, No.4 2019 71-76

    6. 免疫抑制因子を標的としたがん免疫療法 和田 尚
     腫瘍内科 23巻6号 別刷 2019年6月 618‐622

    7. コラム先人の足跡 アレックス・クヌート
     和田 尚、中山睿一 がん免疫療法 Vol.3 No.1 p.50-1, 2019

    8. 「腫瘍特異抗原の同定とその機能」和田 尚
     大腸がんperspective  2019, vol.4 no.2, 4(2), 127-132
  • 2018年

  1. Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. Yasuko Tada; Yosuke Togashi; Daisuke Kotani; Takeshi Kuwata; Eichi Sato; Akihito Kawazoe; Toshihiko Doi; Hisashi Wada; Hiroyoshi Nishikawa; Kohei Shitara. J Immunother Cancer. 2018 Oct 11;6(1):106. doi: 10.1186/s40425-018-0403-1
    PMID: 30314524 PMCID: PMC6186121

  2. Immunoregulatory influence of abundant MFG-E8 expression by esophageal cancer treated with chemotherapy. Kanemura T, Miyata H, Makino T, Tanaka K, Sugimura K, Hamada-Uematsu M, Mizote Y, Uchida H, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M, Wada H, Nakajima K, Takiguchi S, Mori M, Doki Y, Tahara H. Cancer Sci. 2018 Nov;109(11):3393-3402. doi: 10.1111/cas.13785  PMID: 30156356

  3. Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients. Kato R, Yamasaki M, Urakawa S, Nishida K, Makino T, Morimoto-Okazawa A, Kawashima A, Iwahori K, Suzuki S, Ueda R, Mori M, Satoh T, Doki Y, Wada H. Cancer Immunology, Immunotherapy, 67(11), 1673-1683, 2018 Nov. PMID: 30128737  doi: 10.1007/s00262-018-2225-x http://link.springer.com/article/10.1007/s00262-018-2225-x

  4. 免疫・ワクチン療法  岡澤晶子、和田 尚  日本臨床・増刊号 食道癌(第二版) Ⅷ.食道がんの治療
    2018年10月28日発行 76巻増刊号8、409~414

  5. 免疫関連臨床効果判定irRCを用いたがんワクチン症例の再検討
    西田謙太郎、西塔拓郎、浦川真哉、森 正樹、垣見和宏、土岐祐一郎、和田 尚
    癌と化学療法 2018、45(15)、1466-8 10月号

  6. コラム先人の足跡 「魔弾の射手」エールリッヒは「医学界のマスター」
    和田 尚、中山睿一 がん免疫療法 Vol.2 No.1 p.80-1, 2018

  7. 「制御性T細胞と腫瘍制御」 浦川真哉、和田 尚 炎症と免疫 26(2) 110-114 2018


  • 2017年

  1. Kawashima A, Kanazawa T, Goto K, Matsumoto M, Morimoto-Okazawa A, Iwahori K, Ujike T, Nagahara A, Fujita K, Uemura M, Nonomura N, Wada H.Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point molecules. Cancer Immunol Immunother. 2018 Jan;67(1):113-125. doi: 10.1007/s00262-017-2060-5. PMID: 28975380

  2. Takeoka T, Nagase H, Kurose K, Ohue Y, Yamasaki M, Takiguchi S, Sato E, Isobe M, Kanazawa T, Matsumoto M, Iwahori K, Kawashima A, Morimoto-Okazawa A, Nishikawa H, Oka M, Pan L, Venhaus R, Nakayama E, Mori M, Doki Y, Wada H. NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC. J Immunother. 40(4):140–147, 2017 May. doi: 10.1097/CJI.0000000000000162.

  3.  Nagase H, Takeoka T, Urakawa S, Morimoto-Okazawa A, Kawashima A, Iwahori K, Takiguchi S, Nishikawa H, Sato E, Sakaguchi S, Mori M, Doki Y, Wada H. ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017 Feb 1;140(3):686-695. doi: 10.1002/ijc.30475.

  4.  コラム先人の足跡 「グランビーのマウスウーマン、ラスロップ」和田 尚、中山睿一 がん免疫療法 Vol.1 No.2 p.80-1, 2017

  5.  アジュバント入りがんワクチンの開発 岩堀幸太、和田 尚 バイオインダストリー 34 (9) 2017 53-58  Sep.17

  6.  Tregを標的としたがん免疫療法 浦川真哉, 土岐祐一郎, 小島隆嗣, 西川博嘉, 垣見和宏, 岡三喜男  中山睿一, 石田高司,飯田真介,鈴木進, 上田龍三, 和田 尚 腫瘍内科、20(2):137-142、2017

  7. 「次世代アジュバント開発のためのメカニズム解明と安全性評価」 監修 石井 健 シーエムシー出版発行 2017年3月 第4章 前臨床・臨床事例 1 アジュバント入りがんワクチンの開発 岩堀幸太、和田 尚 251-255

  8.  カレントテラピーCurrent Therapy 2017 Vol.35 No.2 p22-26 免疫チェックポイント阻害療法における制御性T細胞の役割 岩堀幸太・和田 尚

  9.  岩堀 幸太, 和田 尚  がん免疫療法の効果予測診断法      ファルマシア Vol. 53(2017) No. 1 p.45-48

  10.  コラム先人の足跡 「ウイリアム・コーリー」和田 尚、中山睿一 がん免疫療法 Vol.1 No.1 p.62-3, 2017

  11.  がんワクチンについて教えてください 岡澤 晶子, 和田 尚 がん免疫療法 1(2) 108-109 2017年9月

  12. 4)タンパクおよび長鎖ペプチドによるワクチン 岡澤晶子・和田 尚  遺伝子医学MOOK 2017年7月31日発行 がん免疫療法 監修:珠玖 洋 第2章 最近のがん免疫療法開発の臨床的成果と位置づけ 3 がんワクチン    31号 (2017)(p.117-122)



  • 2016年

1.      Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y, Sakaguchi S. Nature Medicine 22, 679–684 (2016)

2.      Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Tanaka K, Miyata H, Sugimura K, Kanemura T, Hamada-Uematsu M, Mizote Y, Yamasaki M, Wada H, Nakajima K, Takiguchi S, Mori M, Doki Y, Tahara H. Cancer Sci. 2016 Mar 25. doi: 10.1111/cas.12938.

3.      Liver failures from ultra-short bowel syndrome on the intestinal transplant waiting list: A retrospective study. Noguchi Y, Ueno T, Matsuura R, Kodama T, Deguchi K, Umeda S, Yamamichi T, Nakahata K, Zenitani M, Takama Y, Yamanaka H, Tazuke Y, Okuyama H. Transplant Proc. 2017 Jan - Feb;49(1):135-138. doi: 10.1016/j.transproceed.2016.10.019.

4.      T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies. Velasquez MP, Torres D, Iwahori K, Kakarla S, Arber C, Rodriguez-Cruz T, Szoor A, Bonifant CL, Gerken C, Cooper LJ, Song XT, Gottschalk S. Sci Rep. 6:27130, 2016

5.      CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Bonifant CL, Szoor A, Torres D, Joseph N, Velasquez MP, Iwahori K, Gaikwad A, Nguyen P, Arber C, Song XT, Redell M, Gottschalk S. Mol Ther. 24(9):1615-26, 2016.

6.      Clarifying the biological significance of the CHK2 K373E somatic mutation discovered in The Cancer Genome Atlas database. Higashiguchi M, Nagatomo I, Kijima T, Morimura O, Miyake K, Minami T, Koyama S, Hirata H, Iwahori K, Takimoto T, Takeda Y, Kida H, Kumanogoh A. FEBS Lett. 590(23):4275-4286, 2016.

7.      腫瘍免疫学とがん免疫療法の歴史  和田 尚、中山睿一 実験医学増刊 Vol.34 No.12 1872-1877 2016

8.      CCR4抗体を用いた制御性T細胞除去がん免疫療法  武岡奉均和田 尚 臨床免疫・アレルギー科 Vol65 545-549 2016

9.      消化器がんにおける免疫チェックポイントを標的とした治療戦略  武岡奉均和田 尚 p.160-165 次世代のがん治療薬・診断のための研究開発  技術情報協会 20162月発刊




2015年

1.      Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, Doi T, Suzuki S, Isobe M, Funakoshi T, Kakimi K, Nishikawa H, Udono H, Oka M, Ueda R, Nakayama E. Clin Cancer Res. 21(19):4327-36, 2015.

2.      Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based study. Kawashima A, Berman DM, Peng Y, Mackillop WJ, Siemens DR, Booth CM. Int J Urol. 22(2):163-70, 2015.

3.      R.E.N.A.L. nephrometry score predicts postoperative recurrence of localized renal cell carcinoma treated by radical nephrectomy. Nagahara A, Uemura M, Kawashima A, Ujike T, Fujita K, Miyagawa Y, Nonomura N. Int J Clin Oncol. 2015 in printing.

4.      High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-Up. Yoshioka Y, Suzuki O, Isohashi F, Seo Y, Okubo H, Yamaguchi H, Oda M, Otani Y, Sumida I, Uemura M, Fujita K, Nagahara A, Ujike T, Kawashima A, Yoshida K, Yamazaki H, Nonomura N, Ogawa K. Int J Radiat Oncol Biol Phys. Jun 3: S0360-3016(15)00606-9, 2015.

5.      Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Iwahori K, Kakarla S, Velasquez MP, Yu F, Yi Z, Gerken C, Song XT, Gottschalk S. Mol Ther. 2015 Jan;23(1):171-8.

6.      がん免疫療法とは 1)がん免疫療法の考え方。 岩堀幸太、和田 尚 臨床腫瘍プラクティス vol.11 No.4 p.273-276  2015

7.      PD-1抗体の泌尿器科疾患, 消化器疾患への応用。和田尚 最新医学  70(3):  421 -427 2015

  • 2014年

1.Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients. Mizote Y, Uenaka A, Isobe M, Wada H, Kakimi K, Saika T, Kita S, Koide Y, Oka M, Nakayama E. Vaccine. 32(8):957-64, 2014.

2.Microvessel area of immature vessels is a prognostic factor in renal cell carcinoma. Sato M, Nakai Y, Nakata W, Yoshida T, Hatano K, Kawashima A, Fujita K, Uemura M, Takayama H, Nonomura N. Int J Urol. 21(2):130-4, 2014.

3.Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Oka M, Doki Y, Nakayama E. J Immunother. 37(2):84-92, 2014.

4.Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers. Matsuzaki S, Serada S, Morimoto A, Ueda Y, Yoshino K, Kimura T, Naka T. Expert Opin Ther Targets. 18(4):403-14, 2014.

5.Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A. Matsuzaki S, Enomoto T, Serada S, Yoshino K, Nagamori S, Morimoto A, Yokoyama T, Kim A, Kimura T, Ueda Y, Fujita M, Fujimoto M, Kanai Y, Kimura T, Naka T. Int J Cancer. 134(8):1796-809, 2014.

6.Perioperative venous thromboembolism in patients with gynecological malignancies: a lesson from four years of recent clinical experience. Morimoto A, Ueda Y, Yokoi T, Tokizawa Y, Yoshino K, Fujita M, Kimura T, Kobayashi E, Matsuzaki S, Egawa-Takata T, Sawada K, Tsutsui T, Kimura T. Anticancer Res. 34(7): 3589-95, 2014

7.Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination. Morimoto A, Ueda Y, Egawa-Takata T, Yagi A, Terai Y, Ohmichi M, Ichimura T, Sumi T, Murata H, Kanzaki H, Nakai H, Mandai M, Yoshino K, Fujita M, Kimura T, Saito J, Sobue T, Nishikawa N, Sekine M, Enomoto T, Horikoshi Y, Takagi T. Int J Clin Oncol. In press. 2014 Jul 9

9.Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner. Morimoto A, Serada S, Enomoto T, Kim A, Matsuzaki S, Takahashi T, Ueda Y, Yoshino K, Fujita M, Fujimoto M, Kimura T, Naka T. Oncotarget. 5(17):7776-87, 2014.

10.Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: A population-based study. Kawashima A, Berman DM, Peng Y, Mackillop WJ, Siemens DR, Booth CM. Int J Urol. 2014 in press.

11.High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Saito T, Wada H, Yamasaki M, Miyata H, Nishikawa H, Sato E, Kageyama S, Shiku H, Mori M, Doki Y. Vaccine. 32(45):5901-7, 2014.

1.抑制性T細胞の同定と機能評価。長瀬博次、西塔拓郎、和田 尚、西川博嘉。Surgery Frontier 21(3): 70-75, 2014

2.XIV 特論 胃癌に対する免疫療法。和田 尚、土岐祐一郎。最新胃癌学 -基礎と臨床の最新研究動向-。日本臨床 72巻増刊号1 p735-739

2013年

1. Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. Yokoyama T, Enomoto T, Serada S, Morimoto A, Matsuzaki S, Ueda Y, Yoshino K, Fujita M, Kyo S, Iwahori K, Fujimoto M, Kimura T, Naka T. Int J Cancer.132(2):472-84, 2013.

2. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma. Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T, Naka T. Int J Cancer. 132(2):459-71, 2013.

3.Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. Yokoyama T, Enomoto T, Serada S, Morimoto A, Matsuzaki S, Ueda Y, Yoshino K, Fujita M, Kyo S, Iwahori K, Fujimoto M, Kimura T, Naka T. Int J Cancer.,132(2): 472-84, 2013.

4.WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial. Miyatake T, Ueda Y, Morimoto A, Enomoto T, Nishida S, Shirakata T, Oka Y, Tsuboi A, Oji Y, Hosen N, Nakatsuka S, Morita S, Sakamoto J, Sugiyama H, Kimura T.  J Cancer Res Clin.139(3):457-63, 2013.

5. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Fujiwara S, Wada H, Kawada J, Kawabata R, Takahashi T, Fujita J, Hirao T, Shibata K, Makari Y, Iijima S, Nishikawa H, Jungbluth AA, Nakamura Y, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Nakayama E, Mori M, Doki Y. Br J Cancer. 108(5):1119-25, 2013.

6.Indazole-based potent and cell-active Mps1 kinase inhibitors: Rational design from pan-kinase inhibitor anthrapyrazolone (SP600125)  Kusakabe K-I, Ide N, Daigo Y, Tachibana Y, Itoh T, Yamamoto T, Hashizume H, Hato Y, Higashino K, Okano Y, Sato Y, Inoue, M, Iguchi, M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Yasuo K, Maeda M, Higaki M, Ueda K, Yoshizawa H, Baba Y, Shiota T, Murai, H, Nakamura Y.  Journal of Medicinal Chemistry. 56 (11), 4343-4356, 2013.

8.EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renalcarcinoma, and its level predicts patient outcome. Sato M, Nakata W, Yoshida T, Hatano K, Kawashima A, Fujita K, Uemura M, Takayama H, Nonomura N. Plos One.8(9), 2013.

7. Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer. Hatano K, Nishimura K, Nakai Y, Yoshida T, Sato M, Kawashima A, Mukai M, Nagahara A, Uemura M, Oka D, Nakayama M, Takayama H, Shimizu K, Meguro N, Tanigawa T, Yamaguchi S, Tsujimura A, Nonomura N.                    Int J Clin Oncol. 18(4):704-10, 2013.

9.Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osako M, Ohnishi M, Harada N, Hishida T, Doki Y, Shiku H. J Transl Med. 11:246, 2013.

10. Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells. Shimada K, Serada S, Fujimoto M, Nomura S, Nakatsuka R, Harada E, Iwahori K, Tachibana I, Takahashi T, Kumanogoh A, Kishimoto T, Naka T. Cancer Sci. 104(11):1483-91, 2013

1.RECISTirResponse Criteria. Mogamulizumabの効果判定。和田 尚、西塔拓郎、長瀬博次、土岐祐一郎。腫瘍内科 vol.12 No.4, 394-400  2013

2.2項 がんワクチン タンパクと長鎖ペプチド。和田 尚、中山睿一。ワクチン開発における最新動向  ~規制動向・安全性評価・品質管理・アジュバント・開発事例~    情報機構  2013

3.免疫バイオマーカーと抗腫瘍効果。和田 尚、中山睿一。実験医学 「腫瘍免疫学とがん免疫療法」31122028-20322013

4.癌患者における免疫モニタリング -評価法と国際標準化。和田 尚、中山睿一。医学の歩み 「がんの免疫制御研究と臨床の最前線2449号 871-8772013

5.腫瘍による制御性T細胞の浸潤誘導。 和田 尚、中山睿一。臨床・免疫アレルギー科 第592号 253-2582013

.

バナースペース

大阪大学

〒565-0871
大阪府吹田市山田丘2-2(0803B)

TEL 06-6210-8413
FAX 06-6210-8413